Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 75 Publications

13 Customer Reviews

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
Tankyrase-1 [1]
(Cell-free assay)
1 nM 5 nM 1.5 μM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 NHrVV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm5[IQ1KGR? M3ntbmlEPTB;NT63NFUhKM7:TTC= MXKxPFU2QTZzMx?=
KP6.3 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC3bVk1KGR? NHHhdYNKSzVyPUGwMlQzQCEQvF2g NV2wd2tpOTh3NUm2NVM>
KP7.7 NXjVW25TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XudlQh\A>? NU\OOHg2UUN3ME21O{BvVSB? NED2c4UyQDV3OU[xNy=>
KB2P3.4 NXHj[5pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fvdVQh\A>? Mmj2TWM2OD1zMkSgUUA> MVyxPFU2QTZzMx?=
KB2P1.21 M2rRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXy0JIQ> NUjlZ3RQUUN3ME24PVA4KG6PIB?= MkDLNVg2PTl4MUO=
U373-MG MXrDfZRwfG:6aXOgRZN{[Xl? MVexJO69VSB? NEHBcYwzPCCq MkjmTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NFe5c2QyQDl3NEexNi=>
T98G NVfudoliS3m2b4TvfIlkKEG|c3H5 MX2xJO69VSB? NHnVUZAzPCCq M2m0b2lv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? NUPMeldjOTh7NUS3NVI>
U87-MG NVq1TINJS3m2b4TvfIlkKEG|c3H5 M2L6XFEh|ryPIB?= M33tVlI1KGh? NV7lW|g6UW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= NFG4TmcyQDl3NEexNi=>
UVW M{HJSWN6fG:2b4jpZ{BCe3OjeR?= NUXpdYN7PTByIH7N NFPlc2czPCCq NGjFPZpKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 M4jlTlE5QTV2N{Gy
HeLa M{PIfWZ2dmO2aX;uJGF{e2G7 M2rOXlUxOCCwTR?= MVm0JIg> MWTDZZV{\XNiYTDtc4Rme3RiZHXsZZkhcW5icnXqc4lvcW6pIH;mJJJi\GmjdHnvck1qdmS3Y3XkJGRPSSCkcnXhb5M> NX:2ZlBEOTh7NUS3NVI>
HeLa Ml;DSpVv[3Srb36gRZN{[Xl? M1i3NlEh|ryPIB?= MlrhNlQhcA>? M2jBR2VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2 NX\ON2E6OTh7NUS3NVI>
T98G MmnXSpVv[3Srb36gRZN{[Xl? NFjRcJAyKM7:TTC= MY[yOEBp MULFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? MYmxPFk2PDdzMh?=
L3 MWTDfZRwfG:6aXOgRZN{[Xl? NYLLZ2E4PSEQvF2g MnvGPVYhcA>? NGDtV2VFVVOR Mkj4V4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs NIjzcHYzODF{NES1PS=>
Granta-519 MoXWR5l1d3SxeHnjJGF{e2G7 MnLkOUDPxE1i M{\NcFk3KGh? NHH2c4hFVVOR Moi4V4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? MoXMNlAyOjR2NUm=
BT MoDWR5l1d3SxeHnjJGF{e2G7 MYS1JO69VSB? MmPiPVYhcA>? M2XyVWROW09? MYfTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MVeyNFEzPDR3OR?=
UPN2 NH7JU|lEgXSxdH;4bYMhSXO|YYm= NVHQVnhFPSEQvF2g MlL5PVYhcA>? M2D4S2ROW09? MoHVV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? MYWyNFEzPDR3OR?=
HBL-2 NGXTRmFEgXSxdH;4bYMhSXO|YYm= MmjCOUDPxE1i NY\rR4FDQTZiaB?= MkPLSG1UVw>? NV3Zd4U3W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MX:yNFEzPDR3OR?=
JVM-2 MnnXR5l1d3SxeHnjJGF{e2G7 NUTvXGJwPSEQvF2g NX3ENnZZQTZiaB?= NHrzVHJFVVOR NFfp[2dUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu M{O2TFIxOTJ2NEW5
Z138 M3P4R2N6fG:2b4jpZ{BCe3OjeR?= MW[1JO69VSB? NF;3Nog6PiCq M2K5PGROW09? NXfMWnJ7W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MlLENlAyOjR2NUm=
RWPE NYW4WoN{UW64YYPpeoUhSXO|YYm= NYf0NYxKOjVizszN M1vhWFQ5KGh? MnTZSG1UVw>? NF7uU3lUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v M3XZWFIyPTd3OE[1
VCaP MX3JcpZie2m4ZTDBd5NigQ>? NV7JWZdFOjVizszN M2LxR|Q5KGh? NGLNTWFFVVOR MXzTbYdvcW[rY3HueIx6KHKnZIXj[ZMhTVKJLXTybZZmdiClZXzsJIlvfmG|aX;u MoLXNlE2PzV6NkW=
Mouse H2AX−/− ES Cells Mn\WR5l1d3SxeHnjJGF{e2G7 M13jWFIvPSEQvF2= NYK0ZZczOjBiaB?= MoLUV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs MoHQNlM{PTV2OEm=
Mouse ATM−/− ES Cells MorDR5l1d3SxeHnjJGF{e2G7 NITjbnEzNjVizszN Mn3oNlAhcA>? M2XHPXNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> MVSyN|M2PTR6OR?=
H1650 M2XnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPOcWwzOCEQvF2= NIj4dnMyPDRiaB?= NVXVW2VKUUN3ME2xOU41PyEQvF2= MWGyN|I{QThyOR?=
H1650PTEN+ NWflTpBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjJNGtjOjBizszN MoK4NVQ1KGh? MY\JR|UxRTVyLkizJO69VQ>? MWmyN|I{QThyOR?=
PC-9 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPKW|Q6OjBizszN NH23dVAyPDRiaB?= NVfDTpo5UUN3ME21Mlg5KM7:TR?= MX:yN|I{QThyOR?=
PC-9PTEN− MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGyNEDPxE1? M4LtPVE1PCCq Mo[0TWM2OD14LkWyJO69VQ>? NGTkVpUzOzJ|OUiwPS=>
MDA-MB-231 M{P5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHtOUBl[Xl? NVTHZWxkUUN3ME22Mlkh|ryP MUWyN|c3ODR7Nh?=
MDA-MB-468 Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC3TpBPPSCmYYm= MVTJR|UxRTVwMDFOwG0> MVmyN|c3ODR7Nh?=
BT20 M3TUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHqSoFZPSCmYYm= M{XKUmlEPTB;Nz63JO69VQ>? MV[yN|c3ODR7Nh?=
HCC1143 M4q2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\vOUBl[Xl? MnrXTWM2OD1zMT6xJO69VQ>? NWq1VZJCOjN5NkC0PVY>
HCC1937 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUG1JIRigQ>? NHWxN2JKSzVyPUGyMlYh|ryP M4f6dlI{PzZyNEm2
Hs578t MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLvOUBl[Xl? MlP2TWM2OD13Lk[g{txO MkDRNlM4PjB2OU[=
Hs578t(si) M1PuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHtPGZxPSCmYYm= NHXheGFKSzVyPUeuOUDPxE1? NGXHV24zOzd4MES5Oi=>
BT474 M4LQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfSOUBl[Xl? MkDaTWM2OD1zOT64JO69VQ>? M4rOTFI{PzZyNEm2
JIMT1 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu1JIRigQ>? MmHiTWM2OD15Lkeg{txO MmTBNlM4PjB2OU[=
SKBR3 M4HncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHXOUBl[Xl? MlPETWM2OD1zMT6xJO69VQ>? NWryPXdKOjN5NkC0PVY>
SUM159 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrhXGs2KGSjeR?= NHnkUmtKSzVyPUSuNkDPxE1? MmnmNlM4PjB2OU[=
CAMA1 NICwZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:1JIRigQ>? NETLZnpKSzVyPUG1Mlgh|ryP M1P6clI{PzZyNEm2
MCF7 M3PUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHOOUBl[Xl? MV\JR|UxRTVwODFOwG0> M4XSUlI{PzZyNEm2
T47D Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon4OUBl[Xl? NIKwdWpKSzVyPUmuOkDPxE1? NYXQemRXOjN5NkC0PVY>
HCT116 M332RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWewV2xQOTByIN88US=> NEnicFE1QCCq MYLEUXNQ M1zqO2lEPTB;Mj61JO69VSB? M1\Nd|I1PTd5OUSx
SW1116 NIjSOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCxNFAh|ryP MYG0PEBp NV;rfYtxTE2VTx?= MVXJR|UxRTFyMDFOwG0> NWHGOHE{OjR3N{e5OFE>
HT29 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\OclExOCEQvF2= M1;xNVQ5KGh? MnTBSG1UVw>? MXXJR|UxRTF2Lkeg{txO M4\UNFI1PTd5OUSx
LoVo MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWexNFAh|ryP NX3yUld{PDhiaB?= MV\EUXNQ MkS2TWM2OD1zMz60JO69VQ>? M1vvNFI1PTd5OUSx
HCT-15 M1ToZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nyb|ExOCEQvF2= NELONXk1QCCq NVvBRVhCTE2VTx?= MXHJR|UxRTFyIN88US=> NUTPUWhCOjR3N{e5OFE>
SW48 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rBVFExOCEQvF2= NYG5UIQ3PDhiaB?= NUDiXnk6TE2VTx?= MV7JR|UxRTlwNTFOwG0> NEXqWGQzPDV5N{m0NS=>
C-1 M4PiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTCNJBoOTByIN88US=> M37GSVQ5KGh? M4GwO2ROW09? MmDQTWM2OD15Lk[g{txO Mof5NlQ2Pzd7NEG=
RKO M4TrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn4OYhkOTByIN88US=> MWG0PEBp NEPUT4FFVVOR MnP6TWM2OD13Lkmg{txO MmTVNlQ2Pzd7NEG=
HCT116 NX\P[ph[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLSSHkyODBizszN MVe0PEBp MVzEUXNQ NFfMNVdRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NGfwV2kzPDV5N{m0NS=>
SW1116 NWT5SYNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrkPGcyODBizszN MYK0PEBp MV7EUXNQ MX\Qc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MlrzNlQ2Pzd7NEG=
HT29 MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTZNVAxKM7:TR?= NWDzTmRVPDhiaB?= MnnrSG1UVw>? M1LER3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MnjNNlQ2Pzd7NEG=
LoVo NXnKfXhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNFAh|ryP NVH1PHl6PDhiaB?= MX;EUXNQ MWDQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh M1\KZ|I1PTd5OUSx
SW48 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TDdVExOCEQvF2= M1ntTFQ5KGh? M3TUemROW09? NHTrNW5Rd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NELXNJQzPDV5N{m0NS=>
C-1 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLBNVAxKM7:TR?= NFvtPJA1QCCq M1zBXGROW09? MVTQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh M4HISlI1PTd5OUSx
RKO M4SxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vNZVExOCEQvF2= MYe0PEBp MlLKSG1UVw>? Mn3UVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? Mm\rNlQ2Pzd7NEG=
HCT116 M{[4ZWZ2dmO2aX;uJGF{e2G7 MmTXNVAhdk1? MnX5NVIhcA>? M36zNmROW09? NF3xTnVKdmO{ZXHz[ZMhTE6DIHTveYJt\S2|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i= NVrDSXpYOjR3N{e5OFE>
HT29 Mlj6SpVv[3Srb36gRZN{[Xl? Ml3hNVAhdk1? MnHFNVIhcA>? MYLEUXNQ NF7VdItKdmO{ZXHz[ZMhTE6DIHTveYJt\S2|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i= NVvXUYdSOjR3N{e5OFE>
TE-6 NXSze4lxTnWwY4Tpc44hSXO|YYm= MonoOUDPxE1i NEHPTXEyOiCq M17yUmROW09? MmLTTY5lfWOnczDHNk9OKGG{cnXzeC=> NFTkcGEzPDJzOUG2OC=>
TE-6 NUXDW2JpTnWwY4Tpc44hSXO|YYm= M2DjR|Uh|ryPIB?= MlXMNlQhcA>? NUfrVVdrTE2VTx?= MXfJcoNz\WG|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq NELm[oszPDJzOUG2OC=>
Hep3B NFvW[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HBOFQxKM7:TTC= MmXCO|IhcA>? NFLwOZBFVVOR M2nL[HN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS Mkn0NlUxPzJ5NUK=
Huh7 NWjhSpJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TEe|QxKM7:TTC= M1fCS|czKGh? NImwVopFVVOR MWXTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=> NUPZc2FlOjVyN{K3OVI>
Hep3B MVLGeY5kfGmxbjDBd5NigQ>? NWP5d3dRPDBizszNJC=> MUCyOEBp MVTEUXNQ M1[ze2lv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= MnTrNlUxPzJ5NUK=
Huh7 NIDFb4NHfW6ldHnvckBCe3OjeR?= M2HJSlQxKM7:TTC= NXXGVoVOOjRiaB?= NE\2d49FVVOR MU\JcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? NGr3VHgzPTB5Mke1Ni=>
Hep3B MXXGeY5kfGmxbjDBd5NigQ>? MkDyOFAh|ryPIB?= M{niR|I1KGh? NGDFd2lFVVOR NIfuZZpKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= MX[yOVA4Ojd3Mh?=
Huh7 NGDIfphHfW6ldHnvckBCe3OjeR?= MU[0NEDPxE1i MlfXNlQhcA>? MX3EUXNQ NWjNTWNjUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR Ml2wNlUxPzJ5NUK=
SGC-7901 M3:xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q2TFMxyqEQvF2= NXzEXGI3PDhiaB?= NXjrdFNCTE2VTx?= MlL1Roxw[2tib4jhcIlxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo MlXkNlU4PjdyN{[=
COLO-800 NIDwWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwNESxOlQh|ryP NUHMe5JGW0GQR1XS
EoL-1- M2rYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XFNmlEPTB;MD61OlQ1PiEQvF2= Mni5V2FPT0WU
NCI-H209 NFK4bXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojyTWM2OD1yLkmxOVU3KM7:TR?= NVW4W|VTW0GQR1XS
ES1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwMUG0NFgh|ryP NEmxTFNUSU6JRWK=
NKM-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWzTpdKSzVyPUGuNlU{PDdizszN NWfiOpVkW0GQR1XS
NTERA-S-cl-D1 NFrKR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmqwTWM2OD1zLkOzN|QyKM7:TR?= MmrkV2FPT0WU
MHH-ES-1 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnsN4dKSzVyPUGuOlIxPjdizszN NUX6N5R[W0GQR1XS
ES8 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K2XmlEPTB;MT63NlQyPCEQvF2= MY\TRW5ITVJ?
NCI-H720 M3Prb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJwMkC2PVkh|ryP NEKyPJRUSU6JRWK=
EW-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTwbol7UUN3ME2yMlI4PTN2IN88US=> MoLWV2FPT0WU
D-566MG NUfqPW5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;EdI1rUUN3ME2yMlQ1PTZ6IN88US=> MUfTRW5ITVJ?
697 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme3TWM2OD1{Lki0NVc{KM7:TR?= NFn1U5hUSU6JRWK=
ES5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ETmlEPTB;Mj64PFE5QSEQvF2= MULTRW5ITVJ?
COLO-684 NELEe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTNwNUG2PVYh|ryP MVfTRW5ITVJ?
ML-2 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEKzWpRKSzVyPUOuOlAxPThizszN MXnTRW5ITVJ?
MC-IXC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwNkOzPVMh|ryP NWXHTpRsW0GQR1XS
DB NFe3UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzKT2pKSzVyPUOuOlU1PDhizszN M3S4WXNCVkeHUh?=
HCC2218 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwN{OxNFMh|ryP MorVV2FPT0WU
NCI-H510A NGjDOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF22ZYFKSzVyPUOuPFI4OjRizszN NWLYTm45W0GQR1XS
NCI-H526 M3Pabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jPOmlEPTB;Mz64Olk2QCEQvF2= Ml;yV2FPT0WU
MV-4-11 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfLTWM2OD12LkGzN|M1KM7:TR?= MmPFV2FPT0WU
PA-1 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf3S5pKSzVyPUSuNlUzQSEQvF2= NX7yS2NqW0GQR1XS
EW-22 M2TYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PoUGlEPTB;ND6zOVg3KM7:TR?= M3T1enNCVkeHUh?=
KASUMI-1 MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRwNECxNFkh|ryP Mnv4V2FPT0WU
LU-139 M1HMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm2TWM2OD12Lke1PFI6KM7:TR?= MlPjV2FPT0WU
SBC-1 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;GTWM2OD12LkiwPVA5KM7:TR?= M3PCcHNCVkeHUh?=
H4 M1;4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fE[GlEPTB;ND64PVQ1OyEQvF2= NYL6NpNDW0GQR1XS
EW-11 NUHzUpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXJPYtKSzVyPUWuNFgxPzJizszN NXLhfpEyW0GQR1XS
NBsusSR MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLyTWM2OD13LkGyNFU2KM7:TR?= MnHjV2FPT0WU
RPMI-8226 M1;2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\oPGlEPTB;NT6xOVI1PCEQvF2= NW\ubpZKW0GQR1XS
DEL M2r0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTHdndKSzVyPUWuNlAxODZizszN M3XLVXNCVkeHUh?=
ES4 M{XPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\2b2lEPTB;NT61NVM5QSEQvF2= MUPTRW5ITVJ?
GCT Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorQTWM2OD13LkW2PFU3KM7:TR?= MYLTRW5ITVJ?
NCI-H1048 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTVwOUeyO|Mh|ryP NIP0TFhUSU6JRWK=
NCI-SNU-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13hb2lEPTB;Nj6wNlIh|ryP MX\TRW5ITVJ?
ES7 NFK2U3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTZwMEO1O|ch|ryP NWLqUHlOW0GQR1XS
SW982 M{LEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq0VWFSUUN3ME22MlA6OTN5IN88US=> NILWRYlUSU6JRWK=
L-363 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1iyeWlEPTB;Nj6zN|k4PCEQvF2= M{fkdHNCVkeHUh?=
HT-1080 M4PX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHSboVKSzVyPU[uOFk3QDNizszN M3Ta[3NCVkeHUh?=
HAL-01 NGHOWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv4OZpKSzVyPU[uOVExQSEQvF2= Moe4V2FPT0WU
NB14 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTZwNkSwN|kh|ryP Mo\QV2FPT0WU
EW-13 NVrQPJZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPKcVZKSzVyPU[uO|c1OjRizszN MWPTRW5ITVJ?
NY MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonuTWM2OD14Lkm0OlA2KM7:TR?= Mo\CV2FPT0WU
NCI-SNU-5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTrTWM2OD15LkGwOFM{KM7:TR?= MWDTRW5ITVJ?
MS-1 NF6zUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17sT2lEPTB;Nz6xO|Q6PCEQvF2= NVX6VHBoW0GQR1XS
EW-16 NUPYUZB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTdwM{G4OlEh|ryP MWnTRW5ITVJ?
LU-65 NFjnd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXSO4VKSzVyPUeuOFg1OTdizszN M1:0RXNCVkeHUh?=
HGC-27 M2DrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTdwN{KxO|Mh|ryP M2TIdXNCVkeHUh?=
CTB-1 M3P1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTdwN{[xO|Uh|ryP MWXTRW5ITVJ?
5637 NW\U[FFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Py[mlEPTB;Nz65Nlg3KM7:TR?= M3XMXXNCVkeHUh?=
U251 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTdwOUSwNVYh|ryP M4rmT3NCVkeHUh?=
HOS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\pVIpKSzVyPUiuNlMxODdizszN MmLpV2FPT0WU
DOHH-2 M4fFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrXcFhKSzVyPUiuNlM2QCEQvF2= M1Xk[nNCVkeHUh?=
EW-1 M{\WXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPnUGxKSzVyPUiuN|AxQDhizszN M4XL[nNCVkeHUh?=
BV-173 NU\KVlB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny0TWM2OD16LkW1OVQh|ryP M2rDfnNCVkeHUh?=
8-MG-BA MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ke4s2UUN3ME24MlY5QTh6IN88US=> M1;1TnNCVkeHUh?=
NB69 NXzt[I1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRThwN{C5NlEh|ryP MVrTRW5ITVJ?
NCI-H69 NHHON25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTlwOUC5OlEh|ryP MWXTRW5ITVJ?
RS4-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFzLkKyNFgh|ryP MXXTRW5ITVJ?
ONS-76 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfjT2dtUUN3ME2xNU4zQTR5IN88US=> MYDTRW5ITVJ?
SF539 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf1emZKSzVyPUGxMlQ5QDlizszN MonuV2FPT0WU
HuO-3N1 NUXaToRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;yTWM2OD1zMT61O|k3KM7:TR?= NVvqUHBVW0GQR1XS
NCI-H1651 NHrqclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrDN5hKSzVyPUGyMlMyOTVizszN NFv4R4dUSU6JRWK=
KARPAS-45 M2riWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jqb2lEPTB;MUKuN|c3KM7:TR?= NGLpfYZUSU6JRWK=
SK-NEP-1 M{f0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTSOWxLUUN3ME2xNk41PjB7IN88US=> NFrQfYlUSU6JRWK=
LAMA-84 NV\Fb4ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG2RlhKSzVyPUGzMlExQTVizszN NEmydmRUSU6JRWK=
NCI-H1155 NEK3ZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\nTWM2OD1zMz6yPFU3KM7:TR?= MkXNV2FPT0WU
CTV-1 NWDHRoxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF|LkS0OUDPxE1? MYnTRW5ITVJ?
QIMR-WIL NFnoR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF|Lke4NVQh|ryP MYjTRW5ITVJ?
H9 M3G5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImyS3BKSzVyPUGzMlg1PzVizszN NGTmfndUSU6JRWK=
SK-MEL-1 NILEWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTF|LkmzOFch|ryP Mn;EV2FPT0WU
HD-MY-Z NILWXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF2LkC2N|ch|ryP MoK0V2FPT0WU
TI-73 M3vOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPVR5BKSzVyPUG0MlI{PTZizszN MWXTRW5ITVJ?
JVM-3 MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF3LkW3NVYh|ryP M2\k[XNCVkeHUh?=
D-247MG M3zwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPBeZFKSzVyPUG1MlU6OyEQvF2= MWjTRW5ITVJ?
VA-ES-BJ MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILzWINKSzVyPUG1MlYxQTdizszN NWPY[IdQW0GQR1XS
NOS-1 M1fjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fjPWlEPTB;MUWuOlUzOiEQvF2= NYjoUG1TW0GQR1XS
MOLT-4 NYHCU3FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fBbmlEPTB;MU[uO|UzKM7:TR?= MXzTRW5ITVJ?
Mo-T MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrkTWM2OD1zNz6wPFQ6KM7:TR?= NX:3OGFFW0GQR1XS
NCI-H1770 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknBTWM2OD1zNz6xOVQ{KM7:TR?= NFjJcmhUSU6JRWK=
COLO-320-HSR Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF5LkG4Nlch|ryP NUe0NnhpW0GQR1XS
TE-12 M2XxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nKOWlEPTB;MUeuO|A2PCEQvF2= NIfSTVRUSU6JRWK=
NCI-H82 NYXGbHdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;UTWM2OD1zNz64O|I5KM7:TR?= NFfJRXlUSU6JRWK=
NEC8 NE\2V4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrvSmJKUUN3ME2xPE4yOzF4IN88US=> NGXxXlFUSU6JRWK=
HSC-3 M3:0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHNV|hRUUN3ME2xPE44PDF2IN88US=> M1zpfHNCVkeHUh?=
NCI-H1092 M3zzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnYWmdKSzVyPUG4Mlc2QTVizszN NH[5OJVUSU6JRWK=
NCI-H292 NFqzcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj6TWM2OD1zOT6wOFg6KM7:TR?= NUP2UpE4W0GQR1XS
L-428 MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW3TWM2OD1zOT61OVkh|ryP MUjTRW5ITVJ?
LU-134-A Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ucZNLUUN3ME2xPU42PzJizszN MoToV2FPT0WU
GI-ME-N NIO2fWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvTTWM2OD1zOT61O|Q4KM7:TR?= NFXTUmVUSU6JRWK=
ALL-PO NEn3PFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF7LkW5O|Ih|ryP NV;mZlVrW0GQR1XS
D-283MED NF\neVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVniVI9FUUN3ME2xPU46OTVizszN MnPYV2FPT0WU
D-423MG M13IU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7h[4hKSzVyPUG5Mlk6PjdizszN MUHTRW5ITVJ?
CAKI-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLpTWM2OD1{MD6yNlE6KM7:TR?= NUDCS21nW0GQR1XS
ETK-1 NF\5XJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJyLkK2NVUh|ryP M1XMe3NCVkeHUh?=
G-402 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\2TWM2OD1{MD61N|M1KM7:TR?= NX\Ud5dwW0GQR1XS
HL-60 NUTOPXFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:wRmlEPTB;MkGuNVYyOyEQvF2= MXXTRW5ITVJ?
A2058 NH\ZVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX62SXpSUUN3ME2yNU41PDd5IN88US=> NUnrZYV3W0GQR1XS
CHP-212 NXnke3o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJzLkmwOVEh|ryP MmDUV2FPT0WU
KY821 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJzLkm3OUDPxE1? M3\SN3NCVkeHUh?=
TYK-nu M4LEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPCdIlKSzVyPUKyMlA3PTFizszN NF7lc5RUSU6JRWK=
JVM-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu2TWM2OD1{Mj6yPVg{KM7:TR?= M1fFdHNCVkeHUh?=
KU812 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJ{LkezNVIh|ryP NETtZmlUSU6JRWK=
MKN28 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPLTWM2OD1{Mj65NFE2KM7:TR?= NYfOSoZDW0GQR1XS
ECC10 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rr[2lEPTB;MkOuO|QyKM7:TR?= M4nVOHNCVkeHUh?=
BHT-101 M4HpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjBUHlKSzVyPUK0MlAxODhizszN MmLEV2FPT0WU
DU-4475 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ2LkOzN|ch|ryP MYLTRW5ITVJ?
769-P NWS5TZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrkN45KSzVyPUK0Mlg1PjZizszN MVXTRW5ITVJ?
HEC-1 NXfac3RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ3LkS0OUDPxE1? MlnQV2FPT0WU
MOLT-13 M33jOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX0WIRWUUN3ME2yOU42OzNzIN88US=> MYXTRW5ITVJ?
8505C MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL3[GZKSzVyPUK2MlQ6PzdizszN M36yWHNCVkeHUh?=
GB-1 M{LHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13ubGlEPTB;Mk[uO|E4PiEQvF2= MUjTRW5ITVJ?
SF126 M4PrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnTfZJKSzVyPUK2Mlc3PDhizszN M3\WXnNCVkeHUh?=
A4-Fuk NHX1XFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDKTWM2OD1{Nz6xNlcyKM7:TR?= NYXnVHg1W0GQR1XS
OVCAR-8 M2DrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzBcGlXUUN3ME2yO{4yPTN7IN88US=> NYj2SlJlW0GQR1XS
NCI-H1304 Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\nbHJOUUN3ME2yO{42PCEQvF2= M2X5UnNCVkeHUh?=
GR-ST NILkfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LMVmlEPTB;MkiuNFQ4KM7:TR?= NEDDRYFUSU6JRWK=
G-401 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTlTWM2OD1{OD61NFk3KM7:TR?= NHOyTWhUSU6JRWK=
LXF-289 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq2VGRKSzVyPUK4MlU3PTFizszN NHTFPFZUSU6JRWK=
DBTRG-05MG MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe4e|A2UUN3ME2yPE46OjB2IN88US=> MXrTRW5ITVJ?
YKG-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHVb5BZUUN3ME2yPU45PjhizszN NYrTWnV6W0GQR1XS
GAMG M13nV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTBUWJKSzVyPUK5Mlk6OyEQvF2= NGLDWYhUSU6JRWK=
HCT-116 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP0TWM2OD1|MD6wOVQ5KM7:TR?= MmPKV2FPT0WU
S-117 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXpTWM2OD1|MT6yNlU4KM7:TR?= MkiwV2FPT0WU
NCI-H1693 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXmV3FCUUN3ME2zN{43PTR{IN88US=> M4DMPHNCVkeHUh?=
A427 M3HH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrtTWM2OD1|Mz65PVc3KM7:TR?= NUDwZZlsW0GQR1XS
HT-29 NELkc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm3Unl3UUN3ME2zOE43ODN{IN88US=> NW\jdXRvW0GQR1XS
P12-ICHIKAWA M4S4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PufGlEPTB;M{SuO|Q6OSEQvF2= MWXTRW5ITVJ?
CAL-51 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFriOHFKSzVyPUO1MlA4ODlizszN MluzV2FPT0WU
Ramos-2G6-4C10 M{DSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rYXGlEPTB;M{WuNlQzPSEQvF2= M4Dj[XNCVkeHUh?=
SCH MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Prc2lEPTB;M{[uOFE4PCEQvF2= MWfTRW5ITVJ?
SK-MEL-24 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvYTWM2OD1|Nj65NFQ1KM7:TR?= M{O5b3NCVkeHUh?=
SW1573 NVLWZXVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O5R2lEPTB;M{iuO|IyPiEQvF2= M{PESnNCVkeHUh?=
BALL-1 NFrtU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLtTWM2OD1|OT6yNVI6KM7:TR?= MkCyV2FPT0WU
BE-13 NWP2OlJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3adXRKSzVyPUO5MlMzQSEQvF2= MVHTRW5ITVJ?
GI-1 NVnjS5Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTN7Lki2OFch|ryP NED2WIlUSU6JRWK=
GOTO NYK1UnBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LzWGlEPTB;M{muPVE{QSEQvF2= NVvIdHZ5W0GQR1XS
A673 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jlUWlEPTB;NEGuNFM1OyEQvF2= NWG2NJhkW0GQR1XS
KG-1 NYDZS5pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXLTWM2OD12Mz6zPVQh|ryP MVXTRW5ITVJ?
GP5d M2i2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDDXpB{UUN3ME20OE4xPjZ4IN88US=> NHPINYJUSU6JRWK=
MFM-223 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrpXZpMUUN3ME20OE4yOjJ6IN88US=> NF;hb4FUSU6JRWK=
OAW-42 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLPTWM2OD12ND6yOlQ{KM7:TR?= Mn7rV2FPT0WU
C8166 M3v4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrDTI5EUUN3ME20OU4xQDJ{IN88US=> MWDTRW5ITVJ?
LU-99A M2rIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnsTFJKSzVyPUS2MlE{OjJizszN MUjTRW5ITVJ?
NCI-H23 MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK2TWM2OD12Nj6xO|g2KM7:TR?= MkXLV2FPT0WU
HO-1-N-1 NFqyUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjkTGxKSzVyPUS3MlA6QThizszN MXLTRW5ITVJ?
A3-KAW NXzVXnh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HnR2lEPTB;NEeuNVAxPyEQvF2= MnOyV2FPT0WU
CGTH-W-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPpTWM2OD12Nz61NFY6KM7:TR?= NHf2WIJUSU6JRWK=
DJM-1 NVLqSmNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTR5LkW0NVMh|ryP NXvPZ|JTW0GQR1XS
A101D MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHtemRrUUN3ME20O{43OzV5IN88US=> Ml\iV2FPT0WU
BB30-HNC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mzWWlEPTB;NEiuN|A4OiEQvF2= MWjTRW5ITVJ?
T98G NHXjNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXXV|hxUUN3ME20PE41PjN|IN88US=> NUXFXoI4W0GQR1XS
NCI-H1573 Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLHOVdKSzVyPUS5MlQ1PjJizszN M1nN[nNCVkeHUh?=
MEG-01 NGflbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR7Lke0NVEh|ryP NHHmWlVUSU6JRWK=
WM-115 NELwcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTR7LkmyNlIh|ryP MlTwV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID